Another genetically engineered oncolytic virus, DNX2401, uses the genome of an adenovirusgamma 24 with a cyclic arginine/glycine/aspartic acid (RGD-4C) peptide motif inserted in it and a ∆-24 mutation [178]. DNX2401 preference of infecting cancerous cells was achieved through the addition of RGD-4C, as it permits attachment to integrins, which are ubiquitously present on glioma cells, and overcomes the relative low expression of CARs (coxsakie-adenovirus receptors) [178]. The Delta-24 mutation restricts viral replication to cells defective in the retinoblastoma protein tumour suppressor (RB1), allowing DNX2401 to selectively replicate in tumour cells that have lost RB1 [178]. The latest **data** from an ongoing phase I study (NCT00805376) suggests dramatic responses with long-term survival in recurrent high-grade gliomas and more than 95% in tumour size [179]. Infiltration of T cells with Th1 immune response was observed, as well as an adaptive immune memory effect 2.5 years after a complete response [179].